Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Intricacies of bevacizumab-induced toxicities and their management.

Gressett SM, Shah SR.

Ann Pharmacother. 2009 Mar;43(3):490-501. doi: 10.1345/aph.1L426. Epub 2009 Mar 3. Review.

PMID:
19261963
2.

Understanding and managing the possible adverse effects associated with bevacizumab.

Shord SS, Bressler LR, Tierney LA, Cuellar S, George A.

Am J Health Syst Pharm. 2009 Jun 1;66(11):999-1013. doi: 10.2146/ajhp080455. Review.

PMID:
19451611
3.

Incidence and management of bevacizumab-related toxicities in colorectal cancer.

Saif MW, Mehra R.

Expert Opin Drug Saf. 2006 Jul;5(4):553-66. Review.

PMID:
16774493
4.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
5.

Safety of bevacizumab in patients with metastatic breast cancer.

Hamilton EP, Blackwell KL.

Oncology. 2011;80(5-6):314-25. doi: 10.1159/000328757. Epub 2011 Jul 19. Review.

PMID:
21778772
6.

Managing patients treated with bevacizumab combination therapy.

Gordon MS, Cunningham D.

Oncology. 2005;69 Suppl 3:25-33. Epub 2005 Nov 21. Review.

PMID:
16301833
7.

Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.

Akun E, Okutur K, Seber S, Korkmaz T, Aydin K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G.

J BUON. 2012 Oct-Dec;17(4):669-76.

PMID:
23335523
8.

[Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].

Ge FJ, Xu JM.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):481-6. Review. Chinese. No abstract available.

PMID:
21029688
9.

[Bevacizumab and arterial hypertension or proteinuria: management].

Senellart H, Bennouna J.

Rev Mal Respir. 2008 Jun;25(6):767-72. Review. French.

PMID:
18772832
10.

Adverse events in bevacizumab and chemotherapy: patient management.

Blowers E, Hall K.

Br J Nurs. 2009 Apr 9-22;18(7):424-8. Review.

PMID:
19373187
11.

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.

Hurwitz H, Saini S.

Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34. Review.

PMID:
17145522
12.

Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.

Wu S, Keresztes RS.

Cancer Invest. 2011 Aug;29(7):460-71. doi: 10.3109/07357907.2011.597815.

PMID:
21740083
13.

Using bevacizumab to treat metastatic cancer: UK consensus guidelines.

Miles D, Bridgewater J, Ellis P, Harrison M, Nathan P, Nicolson M, Raouf S, Wheatley D, Plummer C.

Br J Hosp Med (Lond). 2010 Dec;71(12):670-7. Erratum in: Br J Hosp Med (Lond). 2011 Feb;72(2):115.

PMID:
21135762
14.

Managing adverse events in the use of bevacizumab and chemotherapy.

Blowers E, Hall K.

Br J Nurs. 2009 Mar 26-Apr 8;18(6):351-6, 358. Review.

PMID:
19329899
15.

Nursing considerations of bevacizumab use in multiple tumor types.

Gobel BH.

Oncol Nurs Forum. 2007 May;34(3):693-701. Review.

PMID:
17573328
16.
17.

Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.

Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A.

Oncologist. 2011;16(4):432-44. doi: 10.1634/theoncologist.2010-0271. Epub 2011 Mar 25. Review.

18.

[Surgical management of bevacizumab-associated peritonitis due to perforation].

Kube R, Meyer F, Bien N, Schmidt C, Mroczkowski P, Dalicho S, Lippert H.

Zentralbl Chir. 2009 Sep;134(5):462-7. doi: 10.1055/s-0028-1098701. Epub 2009 Sep 15. German.

PMID:
19757347
19.

Managing bevacizumab-related toxicities in patients with colorectal cancer.

Saif MW.

J Support Oncol. 2009 Nov-Dec;7(6):245-51. No abstract available.

PMID:
20380333
20.

[Adverse events related to bevacizumab and the management principles in non-small cell lung cancer].

Cheng G, Zhang L.

Zhongguo Fei Ai Za Zhi. 2010 Jun;13(6):563-7. doi: 10.3779/j.issn.1009-3419.2010.06.001. Review. Chinese. No abstract available.

Supplemental Content

Support Center